We are pleased to share the investment in our client, Boca Biolistics (Boca), by Clairvest Group, Inc. (TSX: CVG), along with Clairvest Equity Partners VI (CEP VI, and collectively Clairvest). The investment closed February 21, 2023.

Founded in 2007, and located in Pompano Beach, Florida, Boca Biolistics is a leading clinical research organization and biomaterials company focused on the procurement, storage, and sale of human biological samples (specializing in infectious diseases and oncology) used for clinical trials and diagnostic development.

Boca has a strong reputation as a trusted vendor in the industry and sources samples from its proprietary network of collection sites internationally. The company also offers in-house analytical laboratory testing and characterization services for internal and third-party samples.

Going forward, Boca will be led by two of its founders, Valentin Adia (CEO) and Michael Morris (COO), both of whom have rolled a significant portion of their equity alongside Clairvest. Boca Biolistics represents Clairvest’s second investment in the life sciences domain.

Located in Toronto, Canada, Clairvest’s mission is to partner with entrepreneurs to help them build strategically significant businesses. Founded in 1987 by a group of successful Canadian entrepreneurs, Clairvest is a top-performing private equity management firm with over C$3.3 billion of capital under management.

Clairvest invests its own capital and that of third parties through the Clairvest Equity Partners limited partnerships in owner-led businesses. Under the current management team, Clairvest has initiated investments in 60 different platform companies and generated top-quartile performance over an extended period.

“We chose to partner with Clairvest because we believe in their partnership-oriented investment style and their ability to help us accelerate our growth over the coming years. We are excited to build on Boca Biolistics’ track record as a leading provider of biosamples and support important biopharma and diagnostic research & development efforts,” said Valentin Adia, CEO of Boca Biolistics.

“Our investment in Boca is the result of a multi-year domain effort in the life sciences industry and represents a compelling opportunity to back an entrepreneurial management team. Boca plays an important role in advancing the development of novel pharmaceutical drugs and diagnostic devices and we are delighted to partner with Valentin and Michael,” said Sebastien Dhonte, Managing Director of Clairvest.

Generational Equity Executive Managing Director, M&A-Technology Practice Leader, David Fergusson, and his team, led by Senior M&A Advisor, Mike LoConte, with the support of Vice President, M&A, Emil Nirkis, successfully managed the transaction. Senior Managing Director Roger Dean established the initial relationship with Boca.